Briacell Therapeutics Corp Stock Market Value
| BCTX Stock | USD 0.53 0.03 5.54% |
| Symbol | Briacell |
Briacell Therapeutics Price To Book Ratio
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Briacell Therapeutics. If investors know Briacell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Briacell Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.89) | Return On Assets (1.26) | Return On Equity (2.06) |
The market value of Briacell Therapeutics is measured differently than its book value, which is the value of Briacell that is recorded on the company's balance sheet. Investors also form their own opinion of Briacell Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Briacell Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Briacell Therapeutics' market value can be influenced by many factors that don't directly affect Briacell Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Briacell Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Briacell Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Briacell Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Briacell Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Briacell Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Briacell Therapeutics.
| 11/23/2024 |
| 12/23/2024 |
If you would invest 0.00 in Briacell Therapeutics on November 23, 2024 and sell it all today you would earn a total of 0.00 from holding Briacell Therapeutics Corp or generate 0.0% return on investment in Briacell Therapeutics over 30 days. Briacell Therapeutics is related to or competes with Fate Therapeutics, Sana Biotechnology, Caribou Biosciences, Arcus Biosciences, Karyopharm Therapeutics, X4 Pharmaceuticals, and Hookipa Pharma. BriaCell Therapeutics Corp., an immuno-oncology-focused biotechnology company, engages in developing immunotherapies for... More
Briacell Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Briacell Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Briacell Therapeutics Corp upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 11.02 | |||
| Information Ratio | 0.0514 | |||
| Maximum Drawdown | 80.91 | |||
| Value At Risk | (10.34) | |||
| Potential Upside | 23.96 |
Briacell Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Briacell Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Briacell Therapeutics' standard deviation. In reality, there are many statistical measures that can use Briacell Therapeutics historical prices to predict the future Briacell Therapeutics' volatility.| Risk Adjusted Performance | 0.0521 | |||
| Jensen Alpha | 0.6625 | |||
| Total Risk Alpha | 0.3126 | |||
| Sortino Ratio | 0.0579 | |||
| Treynor Ratio | (7.27) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Briacell Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Briacell Therapeutics Backtested Returns
Briacell Therapeutics appears to be very risky, given 3 months investment horizon. Briacell Therapeutics secures Sharpe Ratio (or Efficiency) of 0.0439, which signifies that the company had a 0.0439% return per unit of risk over the last 3 months. By analyzing Briacell Therapeutics' technical indicators, you can evaluate if the expected return of 0.55% is justified by implied risk. Please makes use of Briacell Therapeutics' Downside Deviation of 11.02, risk adjusted performance of 0.0521, and Mean Deviation of 8.38 to double-check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Briacell Therapeutics holds a performance score of 3. The firm shows a Beta (market volatility) of -0.0908, which signifies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Briacell Therapeutics are expected to decrease at a much lower rate. During the bear market, Briacell Therapeutics is likely to outperform the market. Please check Briacell Therapeutics' sortino ratio, as well as the relationship between the semi variance and rate of daily change , to make a quick decision on whether Briacell Therapeutics' price patterns will revert.
Auto-correlation | -0.9 |
Excellent reverse predictability
Briacell Therapeutics Corp has excellent reverse predictability. Overlapping area represents the amount of predictability between Briacell Therapeutics time series from 23rd of November 2024 to 8th of December 2024 and 8th of December 2024 to 23rd of December 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Briacell Therapeutics price movement. The serial correlation of -0.9 indicates that approximately 90.0% of current Briacell Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.9 | |
| Spearman Rank Test | -0.62 | |
| Residual Average | 0.0 | |
| Price Variance | 0.05 |
Briacell Therapeutics lagged returns against current returns
Autocorrelation, which is Briacell Therapeutics stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Briacell Therapeutics' stock expected returns. We can calculate the autocorrelation of Briacell Therapeutics returns to help us make a trade decision. For example, suppose you find that Briacell Therapeutics has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Briacell Therapeutics regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Briacell Therapeutics stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Briacell Therapeutics stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Briacell Therapeutics stock over time.
Current vs Lagged Prices |
| Timeline |
Briacell Therapeutics Lagged Returns
When evaluating Briacell Therapeutics' market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Briacell Therapeutics stock have on its future price. Briacell Therapeutics autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Briacell Therapeutics autocorrelation shows the relationship between Briacell Therapeutics stock current value and its past values and can show if there is a momentum factor associated with investing in Briacell Therapeutics Corp.
Regressed Prices |
| Timeline |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Briacell Stock Analysis
When running Briacell Therapeutics' price analysis, check to measure Briacell Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Briacell Therapeutics is operating at the current time. Most of Briacell Therapeutics' value examination focuses on studying past and present price action to predict the probability of Briacell Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Briacell Therapeutics' price. Additionally, you may evaluate how the addition of Briacell Therapeutics to your portfolios can decrease your overall portfolio volatility.